Epidermal growth factor enhances MPC-83 pancreatic cancer cell migration through the upregulation of aquaporin 3
- Authors:
- Weijun Liu
- Kunhua Wang
- Kunmei Gong
- Xiaogang Li
- Kaiyuan Luo
View Affiliations
Affiliations: Department of General Surgery, Kunhua Hospital Affiliated to Kunming Medical College, Kunming, Yunnan 650032, P.R. China, Department of General Surgery, the Fourth Affiliated Hospital of Kunming Medical College, Kunming, Yunnan 650021, P.R. China
- Published online on: June 25, 2012 https://doi.org/10.3892/mmr.2012.966
-
Pages:
607-610
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Aquaporin (AQP) water channels are expressed in high-grade tumor cells of different tissue origins. In this study, we investigated whether AQP3 is expressed in cultured MPC-83 pancreatic cancer cells, whether AQP3 enhances cell migration and the signal pathway mechanism involved. MPC-83 pancreatic cancer cells were pre-treated and treated with EGF at different time points and then analyzed using western blotting. Results showed that epidermal growth factor (EGF) induced the phosphorylation of the EGF receptor (EGFR) and extracellular signal-regulated kinase (ERK), which peaked at 5 min after EGF treatment. EGFR and ERK phosphorylation induced by EGF were inhibited by PD153035 (EGFR tyrosine kinase inhibitor) and U0126 (ERK inhibitor), respectively. EGF increased the activity of AQP3 in a dose- and time-dependent manner in MPC-83 pancreatic cancer cells, which peaked at 24 h after treatment. The activity of AQP3 and cell migration were inhibited by PD153035, U0126 and CuSO4 (AQP3 water transport inhibitor). EGFR/ERK pathway-mediated AQP3 activation and cell migration were stimulated by EGF in cultured MPC-83 pancreatic cancer cells in vitro and this cell signaling pathway is inhibited by the EGFR and ERK inhibitors, which may be used as potential therapeutic targets in the treatment of pancreatic cancer.
View References
|
1
|
Jeyaseelan K, Sepramaniam S, Armugam A, et
al: Aquaporins: a promising target for drug development. Expert
Opin Ther Targets. 10:889–909. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Walz T, Fujiyoshi Y and Engel A: The AQP
structure and functional implications. Handb Exp Pharmacol. 31–56.
2009.
|
|
3
|
Verkman AS, Hara-Chikuma M and
Papadopoulos MC: Aquaporins–new players in cancer biology. J Mol
Med (Berl). 86:523–529. 2008.
|
|
4
|
Sartore-Bianchi A, Bencardino K, Di
Nicolantonio F, et al: Integrated molecular dissection of the
epidermal growth factor receptor (EFGR) oncogenic pathway to
predict response to EGFR-targeted monoclonal antibodies in
metastatic colorectal cancer. Target Oncol. 5:19–28. 2010.
View Article : Google Scholar
|
|
5
|
Perol M and Arpin D: Tyrosine kinase
inhibitors in the management of non-small cell lung cancer. Rev Mal
Respir. 24:6S188–6S197. 2007.PubMed/NCBI
|
|
6
|
Valentini AM, Pirrelli M and Caruso ML:
EGFR-targeted therapy in colorectal cancer: does
immunohistochemistry deserve a role in predicting the response to
cetuximab? Curr Opin Mol Ther. 10:124–131. 2008.PubMed/NCBI
|
|
7
|
Nico B and Ribatti D: Role of aquaporins
in cell migration and edema formation in human brain tumors. Exp
Cell Res. 317:2391–2396. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Papadopoulos MC, Saadoun S and Verkman AS:
Aquaporins and cell migration. Pflugers Arch. 456:693–700. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Giaccone G and Wang Y: Strategies for
overcoming resistance to EGFR family tyrosine kinase inhibitors.
Cancer Treat Rev. 37:456–464. 2011.PubMed/NCBI
|
|
10
|
Mahipal A, McDonald MJ, Witkiewicz A, et
al: Cell membrane and cytoplasmic epidermal growth factor receptor
expression in pancreatic ductal adenocarcinoma. Med Oncol.
29:134–139
|
|
11
|
Steelman LS, Franklin RA, Abrams SL, et
al: Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
Leukemia. 25:1080–1094. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dragovich T and Campen C:
Anti-EGFR-targeted therapy for esophageal and gastric cancers: an
evolving concept. J Oncol. 8041082009.PubMed/NCBI
|
